Avalo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTX research report →
Range $30 – $60
Price Chart
About the company
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
- CEO
- Garry A. Neil
- IPO
- 2015
- Employees
- 33
- HQ
- Wayne, PA, US
Get TickerSpark's AI analysis on AVTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.04B
- P/E
- -4.18
- PEG
- 0.03
- P/S
- 17631.75
- P/B
- 1.92
- EV/EBITDA
- -9.55
- Div Yield
- 0.00%
- Gross Margin
- -16861.02%
- Op Margin
- -154844.07%
- Net Margin
- -170055.93%
- ROE
- -58.03%
- ROIC
- -19.44%
Latest fiscal year · YoY change
- Revenue
- $59.00K-86.6%
- Gross Profit
- $59.00K-92.7%
- Op Income
- $-72,925,000
- Net Income
- $-78,259,000-122.8%
- EPS
- $-5.84-35.2%
- OCF Growth
- -4.9%
- FCF Growth
- -4.9%
- 52W High
- $24.27
- 52W Low
- $8.65
- 50D MA
- $18.10
- 200D MA
- $16.70
- Beta
- 0.79
- RSI (14)
- 55
- Avg Volume
- 1.36M
No earnings-call transcripts are available for AVTX yet.
- Free Float
- 91.7%
- Shares Outstanding
- 52.57M
- Float Shares
- 48.18M
of shares held by institutions
93 13F filers
Buy/sell ratio 0.46. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 804.08K | ▲ 111.45K |
| Two Sigma Advisers, LP | 49.40K | ▲ 49.40K |
| Allostery Investments LP | 9.00K | ▼ 98.14K |
Held by 102 ETFs
Biggest fund positions in AVTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Sullivan Christopher Ryan | other | 37,945 |
| Aug 17, 26 | Sullivan Christopher Ryan | other | 2,876 |
| Aug 18, 26 | Sullivan Christopher Ryan | other | 31,031 |
| Aug 17, 26 | Sullivan Christopher Ryan | other | 2,876 |
| Aug 17, 26 | Sullivan Christopher Ryan | other | 37,945 |
| Aug 18, 26 | Sullivan Christopher Ryan | other | 31,031 |
| Aug 17, 26 | Sullivan Christopher Ryan | sell | 37,945 |
| Aug 18, 26 | Sullivan Christopher Ryan | sell | 31,031 |
| Aug 17, 26 | Sullivan Christopher Ryan | sell | 3,749 |
| Aug 17, 26 | Doyle Mittie | other | 1,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVTX coverage
Recent articles, reports, and earnings notes.
No research on AVTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVTX report →Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
globenewswire.com · Aug 6
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
globenewswire.com · Jul 22
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
globenewswire.com · Jul 7
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
globenewswire.com · Jul 7
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
globenewswire.com · Jun 26
Avalo Therapeutics Appoints Ron Philip to Board of Directors
globenewswire.com · Jun 23
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
globenewswire.com · Jun 16
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.